Literature DB >> 9041356

Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.

B C Jacobs1, M P Hazenberg, P A van Doorn, H P Endtz, F G van der Meché.   

Abstract

Campylobacter jejuni was isolated from stool specimens of 3 patients with Miller Fisher syndrome (MFS) and 2 patients with Guillain-Barré syndrome (GBS). Anti-GQ1b antibodies in serum from all MFS patients cross-reacted with sialidase-sensitive epitopes in the lipopolysaccharide fraction of C. jejuni from these 3 MFS patients. One GBS patient had anti-GM1 antibodies that bound with lipopolysaccharide of C. jejuni from a control patient and from the other GBS patient without anti-GM1 antibodies. This binding was inhibited by cholera toxin but not by pretreatment with sialidase. The C. jejuni isolate from the GBS patient with serum anti-GM1 antibodies did not contain anti-GM1 antibody-binding epitopes. Our results strongly support the hypothesis that anti-GQ1b antibodies in MFS patients are induced during the antecedent C. jejuni infection. In GBS patients, mechanisms other than molecular mimicry may also be involved in the production of anti-GM1 antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041356     DOI: 10.1093/infdis/175.3.729

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Bickerstaff's encephalitis and the Miller Fisher syndrome.

Authors:  J B Winer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

Review 2.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Plant and human aquaporins: pathogenesis from gut to brain.

Authors:  Jama Lambert; Soledad Mejia; Aristo Vojdani
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

4.  Miller Fisher syndrome.

Authors:  Suresh Kumar Gupta; Kunal Kishor Jha; Mhd Diaa Chalati; Losan Tareq Alashi
Journal:  BMJ Case Rep       Date:  2016-10-13

5.  Characterization of the specific interaction between sialoadhesin and sialylated Campylobacter jejuni lipooligosaccharides.

Authors:  Astrid P Heikema; Mathijs P Bergman; Hannah Richards; Paul R Crocker; Michel Gilbert; Janneke N Samsom; Willem J B van Wamel; Hubert P Endtz; Alex van Belkum
Journal:  Infect Immun       Date:  2010-04-26       Impact factor: 3.441

6.  Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.

Authors:  C W Ang; M A De Klerk; H P Endtz; B C Jacobs; J D Laman; F G van der Meché; P A van Doorn
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 7.  Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective.

Authors:  Graham M O'Hanlon; Roland W M Bullens; Jaap J Plomp; Hugh J Willison
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

8.  Campylobacter jejuni lipooligosaccharides modulate dendritic cell-mediated T cell polarization in a sialic acid linkage-dependent manner.

Authors:  Marieke Bax; Mark L Kuijf; Astrid P Heikema; Wouter van Rijs; Sven C M Bruijns; Juan J García-Vallejo; Paul R Crocker; Bart C Jacobs; Sandra J van Vliet; Yvette van Kooyk
Journal:  Infect Immun       Date:  2011-04-18       Impact factor: 3.441

9.  Enhanced, sialoadhesin-dependent uptake of Guillain-Barre syndrome-associated Campylobacter jejuni strains by human macrophages.

Authors:  Astrid P Heikema; Roman I Koning; Sharon Duarte dos Santos Rico; Hans Rempel; Bart C Jacobs; Hubert P Endtz; Willem J B van Wamel; Janneke N Samsom
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

10.  Differentiation of Campylobacter jejuni serotype O19 strains from non-O19 strains by PCR.

Authors:  N Misawa; B M Allos; M J Blaser
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.